Journal of Biotechnology & Biomaterials

Research Article Open Access

Organoid Technology: Modeling Human Diseases and Testing Therapeutics

Tajudeen Zumla*

Auf Tumwebaze Alicon is based at the Department of Research and Development, University of Bosaso Garowe, Somalia

Abstract

Organoid technology has revolutionized biomedical research by providing three-dimensional models that faithfully replicate the architecture and function of human organs. These miniature organ-like structures derived from stem cells or tissue progenitors are invaluable tools for studying human diseases, including cancer, genetic disorders, and infectious diseases. This article explores the applications of organoids in disease modeling, their role in advancing drug discovery, and the implications for personalized medicine.

Keywords: Organoid technology; Disease modeling; Three-dimensional culture; Drug discovery; Personalized medicine

Introduction

Organoids are three-dimensional structures derived from stem cells or tissue-specific progenitor cells that self-organize and mimic the architecture and function of real organs or tissues. These miniature organs replicate key features, including cellular heterogeneity, physiological functions, and structural organization, making them invaluable models for studying human biology in health and disease [1].

Applications in Disease Modeling

Cancer Research: Organoids derived from tumor tissues replicate the complexity of tumors in vivo, enabling researchers to study tumor growth, heterogeneity, and response to treatments. They facilitate personalized medicine approaches by testing drug responses on patient-derived organoids (PDOs), guiding treatment decisions based on individual tumor characteristics.

Genetic Disorders: Organoids derived from patient-specific induced pluripotent stem cells (iPSCs) allow researchers to study genetic mutations and their impact on organ development and function. This approach aids in understanding disease mechanisms and testing potential gene therapies or corrective strategies.

Infectious Diseases: Organoids derived from intestinal, lung, or brain tissues serve as models for studying host-pathogen interactions, disease progression, and screening antiviral or antibacterial drugs. They provide a platform to investigate viral tropism and immune responses in a controlled environment [2].

Advancing Drug Discovery

Organoid technology accelerates drug discovery by offering realistic disease models that better predict human responses compared to traditional cell cultures or animal models. Key contributions include:

High Throughput Screening: Organoid-based assays enable screening of large compound libraries to identify potential drug candidates with therapeutic efficacy and minimal toxicity.

Targeted Therapeutics: By testing drugs on patient-specific organoids, researchers can identify treatments that are most effective against individual variations in disease biology, leading to more targeted and personalized therapies.

Drug Toxicity Testing: Organoids provide a human-relevant platform for assessing drug safety profiles, reducing reliance on animal testing and enhancing translational relevance [3].

Challenges and Future Directions

While organoid technology offers immense potential, several challenges remain:

Complexity and Standardization: Standardizing organoid culture protocols and ensuring reproducibility across laboratories is essential for reliable research outcomes.

Maturity and Functionality: Improving organoid maturity and functionality to better replicate adult tissues and organs remains a priority for enhancing disease modeling accuracy.

Ethical Considerations: Addressing ethical concerns regarding the use of human-derived materials and ensuring informed consent in research involving patient samples [4].

Future directions include

Multi-Organ Systems: Developing interconnected organoid systems to model interactions between organs and systemic diseases.

Integration with Technologies: Combining organoid models with advanced technologies such as microfluidics and CRISPR-Cas9 gene editing to enhance experimental capabilities [5].

Materials and Methods

Materials

Stem Cells or Tissue Progenitors:

Human induced pluripotent stem cells (iPSCs) or adult stem

***Corresponding author:** Tajudeen Zumla, Auf Tumwebaze Alicon is based at the Department of Research and Development, University of Bosaso Garowe , Somalia, E-mail: tajudeenzumlautu@gmail.com

Received: 02-May-2024, Manuscript No: jbtbm-24-139182, **Editor Assigned:** 06-May-2024, pre QC No: jbtbm-24-139182 (PQ), **Reviewed:** 18-May-2024, QC No: jbtbm-24-139182, **Revised:** 21-May-2024, Manuscript No: jbtbm-24-139182 (R), **Published:** 27-May-2024, DOI: 10.4172/2155-952X.1000389

Citation: Tajudeen Z (2024) Organoid Technology: Modeling Human Diseases and Testing Therapeutics. J Biotechnol Biomater, 14: 389.

cells (e.g., intestinal stem cells, lung progenitor cells) for generating organoids.

Culture Media and Supplements:

Basal media supplemented with growth factors (e.g., EGF, FGF) and extracellular matrix components (e.g., Matrigel, collagen) to support organoid growth and differentiation.

Cell Lines and Patient-Derived Samples:

Cancer cell lines or patient-derived tumor samples for establishing tumor organoids (PDOs).

Antibodies and Reagents:

Fluorescently labeled antibodies for immunostaining to characterize organoid structure and marker expression.

Drugs and Therapeutics:

Pharmacological compounds and therapeutic agents for testing drug responses and efficacy in organoids [6].

Methods:

Organoid Establishment and Culture:

Generation: Differentiate iPSCs or isolate tissue progenitors, embed them in extracellular matrix (ECM) like Matrigel, and culture in appropriate media.

Maintenance: Regularly feed with fresh media containing growth factors to support growth and differentiation [7].

Characterization and Validation:

Immunostaining: Use fluorescent antibodies against specific markers to confirm organoid identity and differentiation status.

Histology: Embed organoids in paraffin, section, and stain with hematoxylin and eosin (H&E) to assess morphology and structural integrity.

Disease Modeling:

Cancer: Establish tumor organoids from patient-derived samples or genetically engineered cell lines to mimic tumor heterogeneity and drug responses.

Genetic Disorders: Differentiate iPSCs into organoids to study genetic mutations and disease phenotypes [8].

Drug Screening and Testing:

Drug Treatment: Expose organoids to pharmacological compounds at various concentrations to assess drug efficacy and toxicity.

Functional Assays: Measure biological responses such as cell viability, apoptosis, or metabolic activity using assays like MTT, ATP assays, or live/dead staining.

High Throughput Screening (HTS):

Automate drug screening processes using robotic platforms to handle multiple organoid cultures simultaneously.

Analyze screening results using computational tools to identify promising drug candidates [9].

Patient-Derived Organoids (PDOs):

Establishment: Obtain patient samples, isolate relevant cells, and culture as organoids to model individual disease characteristics.

Drug Response Testing: Assess drug responses in PDOs to guide personalized treatment strategies.

Data Analysis and Interpretation: Quantify and analyze experimental data to evaluate drug efficacy, toxicity, and molecular responses in organoids.

Compare results with clinical data or animal models to validate organoid-based findings [10].

Discussion

Organoid technology represents a groundbreaking approach in biomedical research, offering sophisticated three-dimensional models that closely mimic the structure and function of human organs. This section discusses the transformative impact of organoids in disease modeling and therapeutic testing, highlighting key insights and challenges.

Conclusion

Organoid technology represents a paradigm shift in disease modeling and therapeutic testing, offering a versatile platform to study human biology and advance drug discovery. By bridging the gap between conventional cell cultures and clinical reality, organoids hold promise for personalized medicine approaches tailored to individual patient profiles. As research continues to evolve and technologies advance, organoids are poised to drive innovation in healthcare, leading to more effective treatments and improved patient outcomes across a spectrum of diseases. Continued interdisciplinary collaboration and technological advancements will be crucial in realizing the full potential of organoid-based approaches in transforming biomedical research and clinical practice.

References

1. Zhou J, Su J, Fu X, Zheng L, Yin Z (2017) Microfluidic device for primary tumor spheroid isolation. Exp Hematol Oncol 6: 22.
2. Eicher AK, Berns HM, Wells JM (2018) Translating developmental principles to generate human gastric organoids. Cell Mol Gastroenterol Hepatol 5: 353-363.
3. Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, et al. (2017) Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 49: 1567-1575.
4. Xu H, Lyu X, Yi M, Zhao W, Song Y (2018) Organoid technology and applications in cancer research. J Hematol Oncol 11: 116.
5. Lancaster MA, Knoblich JA (2014) Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345: 1247125.
6. Zacharias WJ, Frank DB, Zepp JA, Morley MP, Alkhaleel FA, et al. (2018) Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 555: 251-255.
7. Chen YW, Huang SX, de Carvalho A, Ho SH, Islam MN, et al. (2017) A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol 19: 542-549.
8. Pasca SP (2018) The rise of three-dimensional human brain cultures. Nature 553: 437-445.
9. Munera JO, Sundaram N, Rankin SA, Hill D, Watson C, et al. (2017) Differentiation of human pluripotent stem cells into colonic organoids via transient activation of BMP signaling. Cell Stem Cell 21: 5-64
10. Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, et al. (2016) Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc 11: 1724-1743.